[AMBIZYGO: phase II study of high dose liposomal amphotericin B (AmBisome) [10 mg/kg/j] efficacy against zygomycosis]

Med Mal Infect. 2008 Jun:38 Suppl 2:S90-1. doi: 10.1016/S0399-077X(08)73003-8.
[Article in French]
No abstract available

Publication types

  • Clinical Trial, Phase II

MeSH terms

  • Amphotericin B / therapeutic use*
  • Amphotericin B / toxicity*
  • Female
  • Humans
  • Male
  • Patient Selection
  • Treatment Outcome
  • Zygomycosis / drug therapy*

Substances

  • liposomal amphotericin B
  • Amphotericin B